Posts

Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

Somatostatin analogues (SSA) control the hormonal hypersecretion in pancreatic and midgut neuroendocrine tumours (NETs), with antiproliferative, antiangiogenic and proapoptotic effects. Lanreotide autogel is a long-acting SSA that is considered the therapy of choice along with octreotide, in controlling symptoms associated with gastroenteropancreatic (GEP)-NETs.